Phuturdex › Diseases › Bone marrow neoplasm
Drugs in development · updated 30 October 2026
Bone marrow neoplasm: drugs in development
As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for bone marrow neoplasm. 3 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Epetraborole | II | 1 | NCT07891533 |
| CK0804 | I | 1 | NCT05423691 |
| PMD-026 | I | 1 | NCT07379125 |
Sorted by most advanced phase and number of active trials.
All 3 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Polycythemia vera 49 drugs
- Thrombocythemia, Essential 43 drugs
- Myelofibrosis 91 drugs
- Myeloproliferative disorders 91 drugs
- Acute myeloid leukemia 314 drugs
- Chronic myelomonocytic leukemia 90 drugs
- Myelodysplastic Syndromes 203 drugs
- Myelodysplastic–myeloproliferative diseases 40 drugs
- Atypical chronic myeloid leukemia 22 drugs
- Precursor lymphoblastic lymphoma/leukemia 163 drugs
- Precursor T-cell lymphoblastic leukemia 61 drugs
- Aplastic anemia 43 drugs
Broader categories
- Neoplasm 671 drugs
- Hematologic neoplasm 216 drugs
- Myeloid leukemia 26 drugs
- Leukemia 153 drugs
- Myelodysplastic–myeloproliferative diseases 40 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D019046 “Bone Marrow Neoplasms”.